# Nuvectis Pharma, Inc.: overview NVCT · Nasdaq · CIK 1875558 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/nvct.md) · [Financials](/companies/nvct/financials.md) · [Filings](/companies/nvct/filings.md) · [Insiders](/companies/nvct/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.24)](/filings/0001104659-25-105939.md) | not reported | [(0.27)](/filings/0001104659-26-055318.md) | [(0.30)](/filings/0001104659-26-090109.md) | [(0.44)](/filings/0001104659-25-105939.md) | not reported | [(0.26)](/filings/0001104659-26-055318.md) | [(0.30)](/filings/0001104659-26-090109.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(3.02)](/filings/0001558370-23-003181.md) | [(1.51)](/filings/0001558370-24-002497.md) | [(1.43)](/filings/0001558370-25-001496.md) | [(1.11)](/filings/0001104659-26-013044.md) | [(1.32)](/filings/0001104659-26-013044.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nvct/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [TANG CAPITAL MANAGEMENT LLC](/funds/1232621.md) | 2026-06-30 | $28.5m | 1,550,000 | | New +1,550,000 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $18.4m | 1,001,285 | | Added +236,844 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $18.4m | 1,000,000 | | New +1,000,000 | | [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $18.4m | 1,000,000 | | New +1,000,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $16.0m | 872,482 | | Added +212,603 | | [IRIDIAN ASSET MANAGEMENT LLC/CT](/funds/1033427.md) | 2026-06-30 | $14.3m | 777,078 | | Added +125,321 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $8.0m | 432,273 | | Added +48,168 | | [Occam Crest Management LP](/funds/2085909.md) | 2026-06-30 | $7.4m | 357,147 | | Reduced −50,000 | | [SPHERA FUNDS MANAGEMENT LTD.](/funds/1496201.md) | 2026-06-30 | $7.0m | 382,945 | | New +382,945 | | [BALDWIN WEALTH PARTNERS LLC/MA](/funds/1021258.md) | 2026-06-30 | $7.0m | 382,015 | | Added +3,390 | ## Recent filings [All 273 filings](/companies/nvct/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-21 | 16:31 ET | [8-K](/filings/0001104659-26-099712.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-099712 | | 2026-08-04 | 09:01 ET | [10-Q](/filings/0001104659-26-090109.md) | Quarterly report, period 2026-06-30 | 0001104659-26-090109 | | 2026-08-04 | 08:25 ET | [8-K](/filings/0001104659-26-090094.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-090094 | | 2026-06-30 | 16:43 ET | [8-K](/filings/0001104659-26-079360.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-079360 | | 2026-06-29 | 16:07 ET | [8-K](/filings/0001104659-26-078823.md) | 8.01 Other events | 0001104659-26-078823 | | 2026-06-23 | 07:00 ET | [8-K](/filings/0001104659-26-076624.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-076624 | | 2026-06-12 | 16:05 ET | [8-K](/filings/0001104659-26-073419.md) | 5.07 Shareholder vote results | 0001104659-26-073419 | | 2026-05-05 | 09:03 ET | [10-Q](/filings/0001104659-26-055318.md) | Quarterly report, period 2026-03-31 | 0001104659-26-055318 | | 2026-05-05 | 07:36 ET | [8-K](/filings/0001104659-26-055264.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-055264 | | 2026-04-27 | 16:37 ET | [DEF 14A](/filings/0001104659-26-049476.md) | Proxy statement, period 2026-06-11 | 0001104659-26-049476 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-013044.md), filed Feb 11, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1875558 - Tickers: NVCT - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.